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Abstract
Objective
A new case of brainstem ischemic necrosis in a young woman with de novo neuroﬁbromatosis
type 2 (NF2) is reported, and given notable similarities to 7 prior cases of brainstem stroke in
the literature, features deﬁning a possible syndrome were sought.
Methods
Case review including detailed clinical assessment, neuroimaging analysis, genetic testing, and
brain biopsy, followed by a multicase analysis.
Results
Brainstem ischemia in juvenile NF2 typically occurs in teenagers without previously known
NF2 as an acute, monophasic presentation with restricted diﬀusion in the midbrain or pons
following a recent hypoperfusion event, normal vascular imaging, obvious intracranial imaging
features of NF2, typical inactivating NF2 alterations, biopsy showing necrosis without small
vessel pathology, and subsequent aggressive NF2 lesion progression.
Conclusions
Brainstem ischemia in juvenile NF2 is a rare syndrome of unclear etiology, possibly reﬂecting an
unknown underlying vascular abnormality; a digenic eﬀect is not excluded.
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GLOSSARY
ADC = apparent diﬀusion coeﬃcient; CPM = central pontine myelinolysis; NF2 = neuroﬁbromatosis type 2.

Neuroﬁbromatosis type 2 (NF2) usually presents in patients
in their early 20s with symptoms related to vestibular
schwannomas. Younger age at onset occurs in nearly 20% of
patients with NF2, however, and in these patients, nonvestibular presentations predominate, including visual

symptoms (cataracts, retinal hamartoma, or optic nerve
sheath meningioma), cutaneous lesions (NF2 skin plaques,
cutaneous schwannomas, or hyperpigmented lesions), transient mononeuropathy of cranial nerves, seizures (often with
focal cortical dysplasia), and symptomatic spinal nerve root

Figure 1 Radiographic features of the case

(A) Aggressive growth pattern of tumors. Note
the enhancement in the left middle cerebellar
peduncle on August 12, 2016, in the region of T2weighted signal change. (B) T2 fluid attenuation
inversion recovery changes across time. The
earlier lesion in 2015 has enlarged and shows
enhancement. Biopsy in this region showed necrosis but was negative for tumor or infection.
(C) Time course of spreading ADC changes. The
duration of depressed ADC is atypically long
compared with the phasic pattern usually seen
in acute stroke. ADC = apparent diffusion
coefficient.
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schwannomas.1,2 We recently encountered a patient with
progressive brainstem necrosis, as shown on serial diﬀusionweighted images and by biopsy. Seven prior published cases
had marked similarities, suggesting an underrecognized syndrome in NF2.

Figure 2 Vascular imaging

Methods
We performed a detailed case review including clinical and
neuroimaging analyses, genetic testing, and brain biopsy.
Multicase analysis was undertaken to observe common features in 16 predetermined categories.3–6

Results
Clinical data
A 25-year-old woman with a history of strabismus surgery in
childhood developed episodes of vertigo. After 6 months of
persistent symptoms, imaging revealed bilateral vestibular and
other cranial nerve schwannomas, multiple meningiomas and
a cervical cord ependymoma, as well as several small focal
white matter lesions in the corona radiata. There was a subtle,
nonenhancing focus of T2-weighted hyperintensity in the L
middle cerebellar peduncle on a December 2015 MRI, adjacent to a subsequent area of restricted diﬀusion (ﬁgure 1).
There was no family history of NF2, although the parents
were not tested or imaged. Single gene testing of
blood lymphocytes detected a germline NF2 variant, c.288_
290delCTT, which deletes a highly conserved proline residue
and is thought to inactivate merlin. A large left lumbar
schwannoma raised concern for malignant peripheral nerve
sheath tumor and was partially resected via an abdominal
approach. There was substantial blood loss requiring transfusion and volume support. Ten days later, she developed
progressive slurred speech, left facial numbness, bilateral hand
weakness, and diﬃculty walking. Blood pressure and serum
sodium were normal. She progressed to a locked-in syndrome
over 4 days with some residual eye movements. Serial MRIs
revealed a multifocal, bilateral, spreading area of markedly
hypointense apparent diﬀusion coeﬃcient (ADC) signal (0.3
× 10−3 mm2/s) in the pons and left middle cerebellar peduncle (ﬁgure 1). At the site of the prior T2 signal change in
the left middle cerebral peduncle, there was subtle enhancement where ADC was less decreased. Vascular imaging, including CT angiogram and a catheter angiogram, showed
a basilar artery diameter of 3.9 mm at the mid pons and
a basilar bifurcation at the level of the dorsum sellae (ﬁgure 2,
A and B) and was midline throughout, thus not meeting
a deﬁnition of dolichoectasia.7–9 The anatomy of the basilar
artery did not change as seen 5 years later on the 2020 MRI
study. Serial ADC maps showed prolonged loss of signal over
time rather than the typical phasic pattern seen after ischemic
stroke. Perfusion maps suggested decreased cerebral blood
volume and cerebral blood ﬂow in the lesion (data not presented). CSF showed a WBC of 5 cells per mm3 but was
otherwise normal including nucleic acid ampliﬁcation tests for
viral infection. Biopsy of the left middle cerebellar peduncle in
Neurology.org/NG

(A) Diameter of the basilar artery at mid pons. The maximal diameter of
3.9 mm did not meet the 4.5-mm threshold for dolichoectasia. The course of
the basilar artery was midline. (B) Tip of the basilar artery. The basilar artery
bifurcated at the level of the dorsum sellae and thus did not meet the criteria
for elongation. Note the persistent right fetal posterior cerebral artery.

the area of initial enhancement revealed white matter, which
varied from near-normal to necrotic. Within the latter, there
was evidence of axonal swelling, mild macrophage inﬁltration,
and scant lymphocytes. Luxol fast blue–Periodic acid–Schiﬀ
stain showed focal loss of myelin staining but with some
fragments showing normal myelin. No vascular pathology was
identiﬁed. PCR analysis of tissue for infection was negative.
Fluorodeoxyglucose-PET 1 month after the onset showed
hypometabolism in the pons. Subsequent MRIs demonstrated some persistent restricted diﬀusion as well as encephalomalacia of the basis pontis and rapid growth of multiple
NF2-related tumors. Four years later, the patient is locked-in
except for upgaze and is deaf in both ears. A mammalian target
of rapamycin inhibitor was started in an attempt to suppress
further growth of the tumors.10,11
Syndrome features
Table 1 shows the ﬁndings of 8 cases with regard to 16 predetermined categories of clinical, imaging, genetic, and
pathologic features.3–6 In addition, a 2019 article from a UK
group described 2 pediatric patients, without clinical details,
who had pontine infarcts. One had renal artery stenosis and
coarctation of the aorta, and a second had vertebral artery
stenosis and a 22q microdeletion.12 Table 2 shows an analysis
of the NF2 variants reported in each case. Overall, the similarities between cases are striking.
Neurology: Genetics | Volume 6, Number 4 | August 2020
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Table 1 Features of the syndrome
Major features

Syndrome average (95%
CI)

Cases (n = 8)

Sex

60% female

Male

2

Female

3a

Unknown

3

Age at dx NF2, y

2, 4, 6, 7, 13, 13, 22, 25a

11.5 (4.5–18.5)
a

Age at brainstem event,
y

2, 4, 7, 13, 13, 15, 22, 25

12.6 (5.5–19.5)

Genetic alteration

c.114G>A (splice donor, VUS); c.115-1G>C (null); c.169C>T (null); NF1 neg; c.288_290delCTTa;
c.447+1G>A (null); c.448-1G>A (null); frameshift, exon 12; deletion exon2

Typical null variants in NF2

De novo

Y, Yb, Yb, Yb, Yb, Yb, Ya; N

Usually de novo

Severity of NF2

M; S, S, S, S, S, S, S, Sa

Severe

Unusual lesions for NF2

N, N, N, N, N, N; Cb Ca++, No VS, E, cauda; white matter lesionsa

Occasional

a

Brainstem compression
by VS at event

N, N, N, N, N, N, N, N

Precipitating event

Diarrhea; fever, cough; menorrhagia; blood loss after pelvic surgerya; no; NR, NR, NR

Yes, possibly
hypoperfusion

Onset

AM, AM, AM, AM, AM, AM; APa; asymptomatic

Acute, monophasic

No

Localization in
brainstem

Left-sided predominant
pons, midbrain

Midbrain

MB, MB, MB

Pons

P, P, P, P, P, Pa

Medulla

MD

Unilateral

U, U, U

Bilateral

Ba

Left

L, L, L, L, La

Right

R, R, Ra

Clinical severity
HTN at onset

M, M, M, M; S, S, S, Sa

Mild to severe

a

N, N, N, N, N, N, N ; NR, NR

No
a

Vascular imaging

Neg, Neg, Neg, Neg, Neg, Neg ; narrowing left ICA; small left MCA

Stroke blood testing

Neg, Neg, Neg, Neg, Neg, Nega; NR, NR

Biopsy features

Normal; rarely narrowed
lumen ICA or MCA
Negative

Reactive astrogliosis, microglia, hyalinized large caliber vessels; necrosis, vessels normal

a

Necrosis; vessels normal

Abbreviations: AM = acute monophasic; AP = acute progressive; B = bilateral; Cb-Ca++ = cerebellar calcification; CI = confidence interval; E = ependymoma;
HTN = hypertension; ICA = internal carotid artery; M = mild; MB = midbrain; MCA = middle cerebral artery; MD = medulla; N = no; Neg = negative; NR = not
reported; P = pons; S = severe; U = unilateral; VS = vestibular schwannoma.
a
Present case.
b
Likely but not explicitly stated.

To summarize the data, the syndrome of brainstem necrosis
in juvenile NF2 typically occurs in teenagers without previously known NF2 as an acute, typically monophasic event in
the midbrain or pons. Some patients have had a recent
hypoperfusion event. MRI shows markedly restricted diﬀusion in the lesion, but vascular imaging is normal. Our case
demonstrated evolution of imaging ﬁndings and showed
4
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some unusual features compared with acute stroke. NF2 imaging features are apparent at the time of diagnosis. Typical
null NF2 alterations are seen, and absence of family history in
most cases suggests a de novo mutation. Biopsy in 2 cases,
including ours, shows necrosis without small vessel pathology.
The early-onset, high number of NF2-related lesions at diagnosis and the subsequent rapid growth suggest an
Neurology.org/NG

Table 2 Analysis of alterations
Alteration

Effect

ACMG variant classification16,17

gnomAD allele
frequency

MutationTaster binary
prediction18

c.114G>A NM_000268.4a

Alteration within used splice
site

Pathogenic: PVS1, PM1, PM2, BP4

0%

Disease causing

c.115-1G>C NM_
000268.4a

Alteration within used splice
site

Pathogenic: PVS1, PM2, PP3

0%

Disease causing

c.169C>T NM_000268.4a

Nonsense

Pathogenic: PVS1, PM1, PM2, PP3,
PP5

0%

Disease causing

c.288_290delCTTb NM_
000268.4

Substitution of highly
conserved proline

Likely pathogenic: PM1, PM2,
PM4, PP3, PP5

0%

Disease causing

c.447+1G>A NM_
000268.4a

Alteration within used splice
site

Pathogenic: PVS1, PM2, PP3

0%

Disease causing

c.448-1G>A NM_
000268.4a

Alteration within used splice
site

Pathogenic: PVS1, PM2, PP3

0%

Disease causing

Frameshift, exon 12

Truncating

NA

NA

NA

Deletion exon 2

Truncating

NA

NA

NA

Abbreviations: ACMG = American College of Medical Genetics; gnomAD = Genome Aggregation Database; NA = not available.
Probable transcript but not explicitly stated in reference.
Current case.

a

b

aggressive form of NF2 in these patients as is often seen in
younger patients.

Discussion
There are remarkable similarities between the cases in the
literature and our patient, and this suggests a discrete clinical
syndrome of which pediatric neurologists and stroke neurologists should be aware. The name brainstem ischemic syndrome in juvenile NF2 is proposed for this rare syndrome.
Our patient seems to have the most clinically devastating
course of those reported to date, and despite the similarities in
the cases, there are some distinctive features, which may be of
value. Our patient was of somewhat older age. Gradual progression over 4 days to a severe neurologic syndrome with
spreading restricted diﬀusion, rather than the monophasic
courses reported before, is also unusual. Perfusion imaging in
our patient showed low cerebral blood ﬂow and blood volume
in the pons, but it was diﬃcult to be certain that ischemia was
the cause of the perfusion changes, and the bilateral progression, the atypically long phasic course of the restricted
diﬀusion, and the absence of vascular ﬁndings on imaging and
biopsy argue against ischemia as the cause. The known focus
of abnormal T2-weighted hyperintensity in the left middle
cerebellar peduncle that was adjacent to the restricted diﬀusion had enlarged at the time of presentation and showed
enhancement, and this seemed likely to represent a tumor, but
biopsy of the area did not support this. Acute vacuolization of
myelin, including that seen with central pontine myelinolysis
(CPM), can produce restricted diﬀusion but not usually to the
degree found in these cases. The asymmetric distribution of
Neurology.org/NG

lesions in the pons was also not consistent with CPM, and
there was no electrolyte abnormality. Delayed hypoxic leukoencephalopathy can show a long course of markedly restricted diﬀusion, but has not been described in the brainstem,
and the preceding events in the patients here were not consistent with this mechanism. An infectious process seems
unlikely given the benign CSF proﬁle and negative PCR
testing. Finally, our patient had deletion of a highly conserved
proline rather than the truncating mutation more commonly
seen in the other cases and in patients with NF2 in general.
Nonetheless, this deletion likely produced a loss of function in
merlin in common with null mutants.
There have been rare cases in which angiographic narrowing
of the internal carotid artery,6 middle cerebral artery (with
middle cerebral artery infarct),13 vertebral artery,12 aorta,12 or
renal artery14 has been seen in NF2, leading those authors to
propose a vascular process. Although well known in NF1,
vasculopathy is not clearly recognized in young patients with
NF2 at this time.1,2,12 Progressive brainstem stroke syndromes have been seen with dolichoectasia of the basilar artery in NF1.15 Our patient did not meet the criteria for
dolichoectasia. It is notable that these brainstem ischemic
events occur in such close anatomic proximity to the uniquely
selective development of vestibular schwannomas in NF2.
Given the rarity of the syndrome of brainstem ischemic syndrome in juvenile NF2, it is possible that a digenic process is at
work. One of the literature reports analyzed the NF1 gene and
found no alterations. Whole-exome sequencing would be
a reasonable consideration in these cases.
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